Amarantus Bioscience Holdings Inc (AMBS)

[Skeetz99]

After positive Phase IIb results in the treatment of levodopa (L-dopa) induced dyskinesia in Parkinson’s disease (DPD), Santhera is now intending to build a partnership for further
development and commercialization of Fipamezole.

A future licensee:
?? will develop and commercialize the product
?? will have the the right to use all data generated by Santhera for development and commercialization
?? may license worldwide rights, but territory of interest to be negotiated

Fipamezole for treatment of levodopa (L-dopa) induced dyskinesia in Parkinson’s disease (DPD) 700+ mio USD peak sales first-in-class opportunity for US + EU ready to enter phase III.